Navigation Links
Flame retardants prove ineffective on fresh-cut Christmas trees
Date:12/22/2008

PULLAUP, WA This Christmas season, think twice about spending money on a commercial flame retardant for your Christmas tree. The good, old-fashioned methodkeeping your tree in a container of fresh wateris probably all you need to keep your tree green and healthy. Researchers have determined that some flame retardants don't work on cut Christmas trees; in fact, in several cases the chemical retardants sped up the drying process and made trees more flammable.

Drs. Gary Chastagner, professor of plant pathology at Washington State University's Puyallup Research Center, and Eric Hinesley, professor of horticulture at North Carolina State University, tested two flame retardants on Douglas-fir and Fraser fir, two of the favorite Christmas tree species in the United States.

According to Chastagner, many cities and municipalities require that chemical flame retardants be used on cut Christmas trees displayed in public buildings. However, the assumption that all flame-retardants are effective on Christmas trees had not been proven. Additionally, there is little information available about the effect of flame-retardants on the quality of trees or boughs. Chastagner and his colleagues wanted to determine if two particular flame-retardants reduced the potential for fire, and find out what effect the chemicals had on the quality (needle retention and moisture status) of the trees.

Surprisingly, neither product tested in the study showed any benefit to the quality or life of the trees. In fact, the chemical used on Douglas-fir caused the branches to dry much faster than non-treated branches. Because ignition from a small source, such as a match, only occurs below a certain moisture level, branches treated with the flame retardant became a fire hazard quicker than non-treated branches.

Because freshly cut Douglas-fir and Fraser fir Christmas trees are almost impossible to ignite and burn when exposed to a small flame, tests were conducted o
'/>"/>

Contact: Michael W. Neff
mwneff@ashs.org
703-836-4606
American Society for Horticultural Science
Source:Eurekalert

Page: 1 2

Related biology news :

1. Study links cat disease to flame retardants in furniture and to pet food
2. A molecular switch turns on the flame in natures blowtorch
3. Flame retardants prove ineffective on fresh-cut Christmas trees
4. Scientists find link between inflamed gums and heart disease
5. SRMs track fire retardants in humans and environment
6. Chemicals used as fire retardants could be harmful, UC-Riverside researchers say
7. LSU professors work to improve efficiency of ethanol fuel
8. Understanding hypertension in African Americans proves elusive
9. Geron Demonstrates hESC-derived cardiomyocytes improve heart function after myocardial infarction
10. Drug could improve pregnancy outcomes in wider range of women with insulin resistance
11. Improved e-jet printing provides higher resolution and more versatility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/8/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leading ... the executive management team will present at the following investor ... Telecom Conference Date: May 18, 2015 Time: 10:40am ... Cowen and Company Technology, Media & ... The New York Palace Hotel, New York, NY ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... of the 1962 Nobel Prize with Francis Crick and Maurice ... DNA, will present "Curing Incurable Cancer" and attend other events ... the James Graham Brown Cancer Center at the University of ... 5, at the Brown Theater, 315 W. Broadway, Louisville. Admission ...
... early stages of a major cause of failure in joint ... avoid additional surgery. More than 1.5 million total joint replacement ... is 90 per cent, almost 10 per cent of implants ... journal Molecular Pharmaceutics . Dong Wang and colleagues ...
... do not rely on oxygen may have played an important ... to a theory that UChicago researcher Albert Colman is testing ... Siberia. He has found that bacteria at the site ... that scientists must take into account as they attempt to ...
Cached Biology News:UofL hosts address by Nobel Laureate, DNA structure co-discoverer James Watson 2Cold case: Siberian hot springs reveal ancient ecology 2Cold case: Siberian hot springs reveal ancient ecology 3
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... 21, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company focused on the development of autologous ... at the International Society for Cellular Therapy (ISCT) ... tendinosis currently in a Phase 1/2 clinical trial.  ... from 5:30 PM to 7:00 PM local ...
(Date:5/20/2015)... , May 20, 2015 ... presented preliminary data demonstrating the ability of the ... fibrosis (IPF) from other interstitial lung diseases (ILDs) ... the classifier,s potential to help thousands of patients ... ambiguity in IPF diagnosis – a frequent challenge ...
(Date:5/20/2015)... , May 19, 2015 Research and Markets ... of the "Global Cell Therapy Market Outlook 2020 ... of cell therapy in tissue and regenerative medicine is ... no other options which could help in the growth ... this segment but they are unable to form new ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
Rabbit polyclonal to hnRNP-U...
... DNase I (RNase-free) (E.C. 3.1.21.1) is ... DNA and chromatin. It functions by hydrolyzing ... a 5'-phosphate and a 3'-hydroxyl group. Ambion's ... purity available and is recommended to degrade ...
... Agarose Gel-Digesting Preparation contains a unique β-agarose ... quantitative recovery of intact DNA and RNA ... following electrophoresis in TAE, TBE, MOPS, or ... directly in the TAE, TBE, MOPS, and ...
... sheer in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us your ... market it internationally. We work under ISO 9001 ...
Biology Products: